Key Points
- Insider sale: Francis Burrows sold 23,726 shares of Kura Oncology (NASDAQ:KURA) on Dec. 18 at an average price of $9.78 for total proceeds of $232,040.28, cutting his direct ownership by 41.29% to 33,735 shares (SEC filing).
- Stock snapshot: KURA trades near $9.84 with a market cap of about $856.3M, a one‑year range of $5.41–$12.49, 50‑day/200‑day moving averages of $10.63/$8.36, and a negative P/E reflecting ongoing losses.
- Analyst and results context: Analysts carry a consensus "Moderate Buy" with an average price target of $26.57, although the company recently missed EPS expectations (–$0.85 vs. –$0.57) and reported negative margins and ROE.
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Francis Burrows sold 23,726 shares of the company's stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.78, for a total transaction of $232,040.28. Following the completion of the transaction, the insider directly owned 33,735 shares in the company, valued at $329,928.30. This trade represents a 41.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Kura Oncology Price Performance
KURA opened at $9.84 on Friday. The stock has a market cap of $856.28 million, a price-to-earnings ratio of -3.97 and a beta of 0.21. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $12.49. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $10.63 and a 200 day moving average price of $8.36.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. Analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently weighed in on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Barclays restated an "overweight" rating and set a $28.00 price target (up previously from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. UBS Group upped their price objective on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, November 14th. Zacks Research upgraded Kura Oncology from a "strong sell" rating to a "hold" rating in a report on Wednesday, November 5th. Finally, Guggenheim started coverage on Kura Oncology in a research report on Thursday, September 4th. They issued a "neutral" rating for the company. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $26.57.
Check Out Our Latest Stock Report on KURA
Hedge Funds Weigh In On Kura Oncology
Large investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its holdings in Kura Oncology by 169.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,912 shares of the company's stock valued at $334,000 after purchasing an additional 35,779 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Kura Oncology by 57.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,544,113 shares of the company's stock valued at $10,191,000 after buying an additional 566,193 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of Kura Oncology by 26.5% in the first quarter. Hsbc Holdings PLC now owns 54,491 shares of the company's stock valued at $351,000 after buying an additional 11,406 shares during the period. Acadian Asset Management LLC acquired a new stake in Kura Oncology during the first quarter worth about $2,180,000. Finally, Los Angeles Capital Management LLC bought a new position in Kura Oncology during the second quarter valued at about $450,000.
Kura Oncology Company Profile
(
Get Free Report)
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
